Capricor Therapeutics Files 8-K on Financials

TL;DR

Capricor Therapeutics dropped an 8-K on Aug 7th detailing their financial condition and operations.

AI Summary

Capricor Therapeutics, Inc. filed an 8-K on August 7, 2024, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 10865 Road to the Cure, Suite 150, San Diego, California.

Why It Matters

This filing provides investors with an update on Capricor Therapeutics' financial performance and operational status, which is crucial for evaluating the company's health and future prospects.

Risk Assessment

Risk Level: low — This is a routine financial reporting filing and does not contain new material events or significant risk factors.

Key Players & Entities

• CAPRICOR THERAPEUTICS, INC. (company) — Registrant
• August 7, 2024 (date) — Date of Report
• 10865 Road to the Cure, Suite 150, San Diego, California (location) — Principal Executive Offices
• 001-34058 (other) — Commission File Number

FAQ

Key Financial Figures

• $0.001 — h Registered Common Stock, par value $0.001 per share CAPR The Nasdaq Capital M

Filing Documents

• capr-20240807x8k.htm (8-K) — 37KB
• capr-20240807xex99d1.htm (EX-99.1) — 166KB
• capr-20240807xex99d1001.jpg (GRAPHIC) — 5KB
• 0001558370-24-011350.txt ( ) — 339KB
• capr-20240807.xsd (EX-101.SCH) — 3KB
• capr-20240807_lab.xml (EX-101.LAB) — 15KB
• capr-20240807_pre.xml (EX-101.PRE) — 9KB
• capr-20240807x8k_htm.xml (XML) — 5KB

02

Item 2.02 Results of Operations and Financial Condition. On August 7, 2024, Capricor Therapeutics, Inc., a Delaware corporation (the "Company"), issued a press release announcing its financial results for the quarter ended June 30, 2024. A copy of the press release is being furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K. The information under Item 2.02 of this Current Report on Form 8-K and Exhibit 99.1 attached hereto is being furnished and shall not be deemed to be filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be incorporated by reference into any of the Company's filings under the Exchange Act, unless expressly set forth as being incorporated by reference into such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits 99.1 Press Release, titled "Capricor Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update", dated August 7, 2024. 104 Cover Page Interactive Data File (formatted as inline XBRL). 2

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized. CAPRICOR THERAPEUTICS, INC. Date: August 7, 2024 By: /s/ Linda Marbn, Ph.D. Linda Marbn, Ph.D. Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR